Found: 9
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2023 · pp. 25–32
Kudriashov G.G., Vinogradova T.I., Zmitrichenko Yu.G., Dogonadze M.Z., Zabolotnyh N.V., Dyakova M.E., Esmedlyaeva D.S., Gavrilov P.V., Azarov A.A., Tochilnikov G.V., Nefedov A.O., Krylova Yu.S., Yablonskii P.K.
Introduction. Lung cancer and tuberculosis, make a significant affect to the morbidity and mortality of the population in Russia and in the world. Strategy of medication therapy has not been developed for cases when these diseases are combined. The aim of the …
ОБЗОР2022 · pp. 3–8
Paltsev M.A., Drobintseva A.O., Mironova E.S., Paltseva E.M., Do Ngoc Hop, Novak-Bobarykina U.A., Leontyeva D.O.
The pathology of the respiratory organs is the leading one in the structure of the general human morbidity. Every year the number of diseases of the respiratory system increases, and the associated mortality increases in parallel. The study of the causes and m…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2020
Musaelyan A.A., Nazarov V.D., Lapin S.V., Chistyakov I.V., Komarov I.V., Tkachenko O.U., Sogoyan M.V., Berdnik E.W., Mazing A.V., Emanuel W.L., Akopov A.L., Orlov S.V., Bagnenko S.F.
Background. Lung cancer is the most frequent cause of cancer mortality. The prevailing type is non-small cell lung cancer (NSCLC), in the treatment of which EGFR tyrosine kinase inhibitors are actively used, as well as a combination of BRAF and MEK inhibitors.…
ОБЗОР2019
Kushlinskii N.E., Fridman M.V., Morozov A.A., Chertkova A.I., Gershtein E.S., Kadagidze Z.G.
The review is devoted to the studies of immune check-point (programmed death) molecules – PD-1 receptor and its ligands PD-L1 and PD-L2, which play an important role in the regulation of immune response. Special attention is paid to soluble (s) forms of PD-1 a…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2019
Musaelyan A.A., Chistyakov I.V., Nazarov V.D., Lapin S.V., Sogoyan M.V., Khalchitsky S.E., Emanuel W.L., Lobachevskaya T.W., Akopov A.L.
Background. Genotyping of the tumor samples is necessary for a personalized approach in the treatment of patients with malignancies. The identification of somatic mutations in EGFR and KRAS genes can help to predict the course of the disease and to individuali…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2018
Deryusheva I.V., Tsyganov M.M., Rodionov E.O., Efteev L.A., Ibragimova M.K., Miller S.V., Tuzikov S.A., Litviakov N.V.
Introduction. Despite the continuous improvement of the surgical method of treatment of patients with non-small cell lung cancer (NSCLC), there is no noticeable tendency to improve survival data. This 5-year index does not exceed 15–25%. In this regard, it is …
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2016
Kit O.I., Vodolazhsky D.I., Maksimov A.Yu., Lazutin Yu.N., Pyltsin S.P., Leyman I.A., Makueva A.M.
Introduction. EGFR mutation and EML4-ALK fusion are the most clinically significant genetic alterations in non-small cell lung cancer. Numerous studies have been devoted to EGFR mutations and their association with phenotypic clinical and pathological characte…
Research article2014
Mazurenko N.N., Kushlinskii N.E.
Lung cancer is one of the most common oncologic diseases in the world and the most frequent cause of the death from malignant neoplasms. Last decade’s studies revealed significant number of molecular events leading to the onset and development of non-small cel…
Research article2013
Mazurenko N.N., Tsyganova I.V., Gagarin I.M., Chuev I.V., Mochalnikova V.V., Kolomeytseva A.A., Gorbunova V.A.
Last successful results in target therapy of cancer were achieved with different tyrosine kinases inhibitors (TKI). Target therapy of non-small cell lung cancer (NSCLC) with EGFR inhibitors gefitinib and erlotinib is effective only in patients with somatic mut…